INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.76
-0.29 (-3.60%)
At close: 4:00PM EDT

7.81 +0.05 (0.64%)
After hours: 5:59PM EDT

Stock chart is not supported by your current browser
Previous Close8.05
Open8.06
Bid7.74 x 900
Ask7.82 x 800
Day's Range7.55 - 8.10
52 Week Range4.10 - 14.00
Volume1,258,323
Avg. Volume632,534
Market Cap572.757M
Beta2.16
PE Ratio (TTM)N/A
EPS (TTM)-3.34
Earnings DateAug 1, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.20
Trade prices are not sourced from all markets
  • NYSE trader: Cannabis stocks are migrating from Canada to the US—a trend here to stay
    Yahoo Finance Video25 days ago

    NYSE trader: Cannabis stocks are migrating from Canada to the US—a trend here to stay

    Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss Canopy Growth Corp (CGC), which begins trading on NYSE today and is the first pure cannabis play to achieve a listing on the exchange.

  • GlobeNewswire9 hours ago

    INSYS Therapeutics Provides an Update on Its Ongoing Transformation

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reiterated its ongoing efforts to fundamentally transform the company. President and Chief Executive Officer Saeed Motahari joined INSYS in April 2017. Nearly 50 percent of the company’s field force are new to the company.

  • ACCESSWIRE12 hours ago

    Trump Looks to Legalize Cannabis, and the Sector will Boom

    LAS VEGAS, NV / ACCESSWIRE / June 18, 2018 / President Donald Trump said recently that he was inclined to support a bipartisan effort in Congress to ease the U.S. ban on marijuana, a proposal that would ...

  • ACCESSWIRE4 days ago

    Today's Research Reports on Trending Tickers: INSYS Therapeutics and Verastem

    NEW YORK, NY / ACCESSWIRE / June 15, 2018 / U.S. market ended mostly higher on Thursday, as rallies from tech sector drove the Nasdaq to new intraday and closing records. The Dow Jones Industrial Average ...

  • GlobeNewswire5 days ago

    Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection

    Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option for receiving a timely dose of epinephrine to avoid a potentially fatal outcome. INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. In a pharmacokinetics study involving 60 people with seasonal allergies, preliminary results showed that the bioavailability of the company’s novel, proprietary formulation of epinephrine delivered intranasally was similar to that of intramuscular injection with EpiPen® (0.3 mg).

  • What You Must Know About INSYS Therapeutics Inc’s (NASDAQ:INSY) Major Investors
    Simply Wall St.6 days ago

    What You Must Know About INSYS Therapeutics Inc’s (NASDAQ:INSY) Major Investors

    Today, I will be analyzing INSYS Therapeutics Inc’s (NASDAQ:INSY) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affectRead More...

  • Reuters14 days ago

    Florida doctor admits taking kickbacks from Insys, others

    A Florida doctor has admitted, as part of a plea deal, that he received kickbacks from Insys Therapeutics Inc in exchange for writing prescriptions for a powerful fentanyl-based pain medicine. Dr. Michael Frey, 46, pleaded guilty on Monday in federal court in Fort Myers, Florida, to conspiring to receive kickbacks from a medical equipment provider and a pharmacy sales representative.

  • GlobeNewswire14 days ago

    INSYS Therapeutics to Present at Jefferies Global Healthcare Conference

    PHOENIX, June 04, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, ...

  • Reuters19 days ago

    Minnesota sues opioid maker Insys over improper drug marketing

    Minnesota on Wednesday became the latest state to sue Insys Therapeutics Inc, accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug. The lawsuit by Minnesota Attorney General Lori Swanson alleged that the company marketed the opioid drug intended to alleviate pain in cancer patients for unapproved uses. It added to the legal woes of Insys, whose former top executives have been caught up in a federal criminal investigation involving the drug, Subsys.

  • Associated Press19 days ago

    Minnesota sues Arizona-based opioid manufacturer

    ST. PAUL, Minn. (AP) — Minnesota's attorney general is suing an Arizona-based pharmaceutical company, alleging it illegally marketed a painkiller made from the synthetic opioid fentanyl.

  • Thomson Reuters StreetEvents19 days ago

    Edited Transcript of INSY earnings conference call or presentation 8-May-18 9:00pm GMT

    Q1 2018 INSYS Therapeutics Inc Earnings Call

  • INSYS Gets Negative FDA Recommendation for Pain Candidate
    Zacks26 days ago

    INSYS Gets Negative FDA Recommendation for Pain Candidate

    INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.

  • Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It
    Motley Fool26 days ago

    Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It

    The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.

  • GlobeNewswire27 days ago

    INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, confirmed today that an expert panel convened by the U.S. Food and Drug Administration (FDA) voted not to recommend approval of the company’s New Drug Application (NDA) for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain. “We appreciate the panelists’ perspective and guidance,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life.

  • This Pot Stock's First-Quarter Report Is Creating All the Wrong Buzz
    Motley Foollast month

    This Pot Stock's First-Quarter Report Is Creating All the Wrong Buzz

    This potential turnaround candidate is still headed in the wrong direction.

  • The Wall Street Journallast month

    [$$] U.S. Joins Whistleblower Suits Against Opioid Maker

    Its ex-chief executive officer, John Kapoor, and several former top executives have been charged with conspiracy to illegally distribute Subsys, a mouth-spray form of fentanyl that is approved by the Food and Drug Administration to treat cancer-related pain. Mr. Kapoor has denied wrongdoing and pleaded not guilty. Shares of Insys fell 6% on Tuesday.

  • Reuterslast month

    Insys sees no change in estimated litigation costs

    Insys Therapeutics Inc said on Tuesday that it believed a previously estimated $150 million would be sufficient to cover expenses from an ongoing litigation related to the company's sales practises. The news comes a day after the U.S. Department of Justice joined a whistleblower lawsuit alleging Insys paid kickbacks to doctors. The company continues to have an ongoing dialogue with the DOJ regarding this investigation, Insys said on Tuesday.

  • GlobeNewswirelast month

    INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts

    In December 2013, INSYS received a subpoena from the Office of Inspector General (OIG) of the Department of Health and Human Services (HHS), which notified the company of the commencement of an investigation by the DOJ’s Civil Division into the company’s sales and commercial practices and resulted in the company’s corresponding public disclosure. As is often the case, this four-and-a-half-year investigation has been conducted in concert with certain whistleblower litigation that was filed under seal prior to and during the course of the DOJ’s investigation.

  • Reuterslast month

    U.S. joins whistleblower case against Insys over kickbacks

    The U.S. Department of Justice has joined whistleblower litigation accusing Insys Therapeutics Inc of trying to generate more profit by paying kickbacks to doctors to prescribe powerful opioid medications. It adds firepower to the civil litigation as Insys tries to resolve a federal probe into its marketing of Subsys, a spray form of fentanyl. Six U.S. states - California, Colorado, Indiana, New York, North Carolina and Virginia - also joined whistleblower litigation against Insys, according to the filing in U.S. District Court in Los Angeles.

  • Reuterslast month

    U.S. joins lawsuits against opioid maker Insys over kickback scheme

    The U.S. Department of Justice has joined lawsuits accusing Insys Therapeutics Inc of paying kickbacks to doctors to prescribe a powerful opioid medication, in an effort to generate more profit. According to a filing made public on Monday in Los Angeles federal court, the department and six U.S. states intervened in whistleblower litigation against Insys, which has said it had been trying to negotiate a settlement of a federal probe into its marketing of fentanyl-based Subsys. The litigation followed a wave of related criminal cases against medical practitioners and former executives and sales representatives employed by Chandler, Arizona-based Insys, including its billionaire founder John Kapoor.

  • Why Marijuana Stock Insys Therapeutics Inc. Gained 16.1% in April
    Motley Foollast month

    Why Marijuana Stock Insys Therapeutics Inc. Gained 16.1% in April

    Shares of the small-cap biotech climbed following news that the company would proceed with inhalation-based dronabinol delivery tests.

  • I Was Flat-Out Wrong About This Marijuana Stock
    Motley Foollast month

    I Was Flat-Out Wrong About This Marijuana Stock

    Insys Therapeutics continues to flounder with no rebound in sight.

  • Associated Presslast month

    Insys Therapeutics: 1Q Earnings Snapshot

    The Chandler, Arizona-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 19 cents per share. The results matched Wall Street ...

  • GlobeNewswirelast month

    INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has agreed to an exclusive license partnership with Lunatus for commercialization of SUBSYS® (fentanyl sublingual spray) in the Middle East. Based in Dubai with satellite offices across the Gulf Cooperation Council, Lunatus will be the exclusive licensee for SUBSYS® in Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates. “Partnering with Lunatus will make SUBSYS® available to adult cancer patients in the licensed territory who are suffering episodes of breakthrough cancer pain despite receiving around-the-clock opioid therapy,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.

  • GlobeNewswirelast month

    INSYS Therapeutics Reports First Quarter 2018 Results

    Cannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS ® revenue continue. PHOENIX, May 08, 2018-- INSYS Therapeutics, Inc., a leader in the development, ...